Shanghai Universal Biotech Co (301166) Fair Value & Analysis
Healthcare · CN · Market cap 2.3B CNY
Fair value as of: Jul 9, 2026
From 1 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from ¥104.75 to ¥18.25 (−82.6%) since Jun 24, 2026. Share price −4.4% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥25.60 – ¥33.66 · fair‑value band ¥12.05 – ¥22.81 · the ¥26.31 price screens above the ¥18.25 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shanghai Universal Biotech Co (301166) currently trades at ¥26.31, while our model-based Fair Value estimate is ¥18.25 — implying the stock looks roughly 30.6% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Shanghai Universal Biotech Co generated revenue of 1.1B CNY at a net margin of -2.2%. Revenue grew 19.8% year over year. It earns a return on equity of -1.3%. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥12.05 (bear case) to ¥22.81 (bull case); at ¥26.31, the current price sits above that range. The share trades about 26% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -31%, 301166 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents. It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, technology incubation and other services, as well as experimental services and software solutions. The company also sells products online. It serves colleges and universities, research institutes, hospitals, and biomedical companies. The company was founded in 2004 and is based in Shanghai, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Universal Biotech Co reported revenue of ¥1.1B in FY2025 versus ¥1.1B in FY2021, a compound −0.6%/yr. Reported net income was −¥22.9M in FY2025.
Is 301166 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Universal Biotech Co (301166) undervalued?
What is the fair value of 301166?
What is the quality score of 301166?
What is the revenue of Shanghai Universal Biotech Co (301166)?
What is the net profit margin of 301166?
Does Shanghai Universal Biotech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.